Abstract: The invention relates to stabilized subtilisin proteases wherein one or more prolines is substituted for a native amino acid at stabilizing positions defined both by the range of the dihedral angles in the primary structure present at the substitution site and by selected characteristics of the protease secondary structure in the vicinity of the substitution site, to nucleotide sequences that encode the stabilized proteases, and to host organisms that contain the nucleotide sequences encoding the stabilized proteases.
Type:
Grant
Filed:
November 11, 1993
Date of Patent:
January 12, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Claus Von Der Osten, Sven Branner, Allan Svendsen, Lisbeth Hedeg.ang.rd, Nina Eriksen, Maarten Robert Egmond, Eric Casteleijn
Abstract: The present invention is directed to a method for screening samples for the identification of agents exhibiting potential fungicidal and insecticidal activity for a wide variety of agricultural, medical and pharmaceutical uses. The method utilizes cells that comprise a plasmid-born CTS gene of Saccharomyces cerevisiae, which allows for over expression of chitinase.
Abstract: The present invention relates to a method and apparatus for inspecting entities comprising liquid-filled containers for one or more test parameters of the liquid, the container, or both, by rotating and axially line scanning said entities and comparing said scans electronically, after which entities exhibiting one or more unacceptable test parameters are identified and separated from entities exhibiting acceptable test parameters.
Type:
Grant
Filed:
December 7, 1994
Date of Patent:
June 4, 1996
Assignee:
Novonordisk A/S
Inventors:
Flemming Manique, Tommy Martinussen, Gert Nielsen
Abstract: A method for measuring the presence of traces of substance in air by providing in a cuvette a substrate reacting with the substance by changing its opacity, passing at a defined flow rate air from the air body to be checked through the substrate, measuring the development of opacity. A portable apparatus comprises a housing (1, 101) holding a cuvette (131) containing a substrate (3, 103), an inlet tube (28) leading to the bottom of the cuvette, a pump (13) sucking air from the cuvette through a flow monitor (138) controlling the pump, a spectrophotometer lamp (19, 119) and a photo-diode (20) on opposite sides of the cuvette (131), a monitor monitoring the level (4, 104) of the substrate in the cuvette, and a monitor (23, 123) monitoring the temperature of the substrate, a computer (24) receiving signals from the photodiode (20), the level monitor, and the temperature monitor to calculate a temperature and level compensated indication of the substrate opacity.
Type:
Grant
Filed:
October 5, 1994
Date of Patent:
May 7, 1996
Assignee:
Novo Nordisk A/S
Inventors:
Grethe Saugmann, Johannes Poulsen, Bjarne B.o slashed.ving, Mads Christian Hage Nielsen
Abstract: A blood sampler comprises a small chamber having a stiletto mounted air-tightly through a flexible top wall with a pointed end of the stiletto positioned inside the chamber opposite an opening in the bottom part of the chamber. The sampler is designed to be mounted in a tool which compresses the chamber by pressing the flexible top wall against the bottom of the chamber. Further, the tool has means for imparting an impact on a blunt outer end of the stiletto to drive the stiletto further through the top wall to make its sharp end protrude through the opening in the bottom part into the skin to which the sampler may be attached by an adhesive. When the sampler is ejected from the tool, it regains its original shape, providing in the chamber a vacuum for sucking blood from the perforated skin into this chamber.
Abstract: The new casein hydrolyzate does not contain any unhydrolyzed casein and is characterized by a defined molecular weight distribution. The method is characterized by being performed by means of three defined proteolytic enzymes and a non-pH star method. The casein hydrolyzate exhibits an optimal balance between DH, free amino acids, bitterness and yield.
Abstract: The present invention relates to the gibbon ape leukemia virus (GALV) receptor protein and gene, as well as methods for regulating viral entry into cells.